Account
Inquiry
QSC Tirzepatide is a novel dual receptor agonist targeting both the glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIP receptor). As a research compound, it demonstrates potential applications in metabolic studies.
The molecular structure of QSC Tirzepatide features a PEG modification on the lysine side chain, which enhances water solubility and stability. This modification contributes to its extended half-life and improved pharmacokinetic properties compared to native incretin peptides.
In research settings, QSC Tirzepatide has shown promising results in glucose metabolism studies. The dual agonist activity at both GLP-1 and GIP receptors may offer synergistic effects on insulin secretion and appetite regulation.
Our QSC Tirzepatide is produced under strict quality control standards, ensuring high purity and consistency for research applications. The product is available in various packaging options to meet different laboratory requirements.
Important Note: This product is supplied for research use only. Not for human consumption or diagnostic use. Researchers should handle all peptide compounds with appropriate safety precautions.
